| Literature DB >> 25678021 |
Jean-Claude Trinchet1, Valérie Bourcier1, Cendrine Chaffaut2, Mohand Ait Ahmed1, Setty Allam3, Patrick Marcellin4, Dominique Guyader5, Stanislas Pol6, Dominique Larrey7, Victor De Lédinghen8, Denis Ouzan9, Fabien Zoulim10, Dominique Roulot11, Albert Tran12, Jean-Pierre Bronowicki13, Jean-Pierre Zarski14, Odile Goria15, Paul Calès16, Jean-Marie Péron17, Laurent Alric18, Marc Bourlière19, Philippe Mathurin20, Jean-Frédéric Blanc21, Armand Abergel22, Lawrence Serfaty23, Ariane Mallat24, Jean-Didier Grangé25, Catherine Buffet26, Yannick Bacq27, Claire Wartelle28, Thông Dao29, Yves Benhamou30, Christophe Pilette31, Christine Silvain32, Christos Christidis33, Dominique Capron34, Gérard Thiefin35, Sophie Hillaire36, Vincent Di Martino37, Pierre Nahon1, Sylvie Chevret2.
Abstract
UNLABELLED: Various critical events, liver related or not, occur in patients with compensated cirrhosis, but their respective burden remains to be prospectively assessed. The aim of this prospective cohort study involving 35 French centers was to capture the whole spectrum of complications occurring in compensated viral cirrhosis (VC) using competing risks analyses. Inclusion criteria were: histologically proven cirrhosis resulting from hepatitis C virus (HCV) or hepatitis B virus (HBV); Child-Pugh A; and no previous hepatic complications. The cohort was considered as a multistate disease model, cumulative incidences (CumIs) of events were estimated in a competing risks framework. A total of 1,654 patients were enrolled from 2006 to 2012 (HCV, 1,308; HBV, 315; HCV-HBV, 31). During a median follow-up of 34 months, at least one liver nodule was detected in 271 patients, confirmed as hepatocellular carcinoma (HCC) in 128 (4-year cumI: 10.5%) and cholangiocarcinoma in 3. HCC incidence was higher in HCV (4-year cumI: 11.4% vs. 7.4%; P = 0.05). HCC fulfilled Milan criteria in 79.3%, leading to curative treatment in 70.4%. Liver decompensation occurred more frequently in HCV patients (4-year cumI: 10.8% vs. 3.6%; P = 0.0004). Virological eradication/control was achieved in 34.1% of HCV and 88.6% of HBV patients and was associated with a marked decrease in HCC, decompensation, and bacterial infection incidences. Survival was shorter in HCV patients (4-year cumI: 91.6% vs. 97.2%; P = 0.0002). Death (n = 102; missing data: 6) was attributed to liver disease in 48 (47%; liver cancer: n = 18; miscellaneous, n = 30) and extrahepatic causes in 48 (47%; bacterial infection: n = 13; extrahepatic cancers: n = 10; cardiovascular events: n = 5; miscellaneous, n = 20).Entities:
Mesh:
Year: 2015 PMID: 25678021 DOI: 10.1002/hep.27743
Source DB: PubMed Journal: Hepatology ISSN: 0270-9139 Impact factor: 17.425